Dose-dependent effects of curcumin on 22Rv1 prostate cancer cell line
Molecular Biology Reports · 2025-12 · 52 (1)
DOI: 10.1007/s11033-025-10448-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, online erschienen am 26.03.2025. Verfasst von Giovanni Tossetta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126, Ancona, Italy. Hauptthemen laut MEDLINE: Curcumin, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università Politecnica delle Marche.
Abstract (Originalsprache)
Background
Prostate cancer (PCa) is the second most frequent cancer type in the male population over 66 years. Curcumin is a polyphenolic natural compound extract from the rhizomes of Curcuma longa Linn ( Zingiberaceae family) which showed important anticancer effects by inhibiting cell proliferation and inducing apoptosis in several cancer types. Recently, some studies reported that oral curcumin lowered PSA levels, but it did not modify the clinical outcomes in patients with prostate cancer who received intermittent androgen deprivation (IAD). Other studies reported that high concentrations of curcumin were toxic for patients. Methods and results In this study we showed that low doses of curcumin can induce senescence-like effects in 22Rv1 cell line while higher concentrations have cytotoxic effects. Five,15 and 30 µM curcumin blocked cell cycle in G2/M phase but only 15 and 30 µM curcumin induced cell death. In addition, an increased expression of p21, a known senescence marker, was detected in 22Rv1 cells treated with curcumin in every experimental condition. However, the expression of p16, another known senescence marker, increased only to 30 µM curcumin.
Conclusion
In the context of personalized approach in PCa care, we suggest that the appropriate concentration of curcumin used in combination with radiotherapy or with androgen deprivation therapy (ADT) could be taken into consideration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126, Ancona, Italy.
- Scientific Direction, IRCCS INRCA, 60124, Ancona, Italy.
- Hematology Laboratory, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, 60126, Ancona, Italy.
- Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126, Ancona, Italy. d.marzioni@univpm.it.
- IRCCS INRCA, 60124, Ancona, Italy. d.marzioni@univpm.it.
- Department of Biomedical Sciences and Public Health, Section of Pathological Anatomy, Università Politecnica delle Marche, 60126, Ancona, Italy.
Förderung
- Università Politecnica delle Marche
Zitieren
APA
Tossetta, G., Fantone, S., Busilacchi, E. M., Marzioni, D., & Mazzucchelli, R. (2025). Dose-dependent effects of curcumin on 22Rv1 prostate cancer cell line. Molecular Biology Reports, 52(1). https://doi.org/10.1007/s11033-025-10448-9
Vancouver
Tossetta G, Fantone S, Busilacchi EM, Marzioni D, Mazzucchelli R. Dose-dependent effects of curcumin on 22Rv1 prostate cancer cell line. Molecular Biology Reports. 2025;52(1). doi:10.1007/s11033-025-10448-9
BibTeX
@article{Tossetta2025,
author = {Tossetta, Giovanni and Fantone, Sonia and Busilacchi, Elena Marinelli and Marzioni, Daniela and Mazzucchelli, Roberta},
title = {Dose-dependent effects of curcumin on 22Rv1 prostate cancer cell line},
journal = {Molecular Biology Reports},
year = {2025},
volume = {52},
number = {1},
doi = {10.1007/s11033-025-10448-9}
}
EUVIMED